Lenalidomide after stem-cell transplantation for multiple myeloma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Multiple Myeloma
  • Stem Cell Transplantation
  • Thalidomide

abstract

  • Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00114101.).

authors

publication date

  • May 10, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3744390

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1114083

PubMed ID

  • 22571201

Additional Document Info

start page

  • 1770

end page

  • 81

volume

  • 366

number

  • 19